methylprednisolone has been researched along with favipiravir in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Baba, T; Hagiwara, E; Higa, K; Ikeda, S; Iwasawa, T; Kaneko, T; Kitamura, H; Kitayama, T; Komatsu, S; Murohashi, K; Nakazawa, A; Niwa, T; Oda, T; Ogura, T; Okabayashi, H; Okuda, R; Otoshi, R; Sato, Y; Sekine, A; Shintani, R; Yamaya, T | 1 |
| Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y; Yoshimatsu, L | 1 |
| Uslu, S | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| Fukuoka, S; Imai, T; Kishaba, T; Maeda, A; Nabeya, D; Nagano, H; Narita, M; Shiiki, S; Takakura, S; Yokoyama, S | 1 |
| Alkan, M; Demirkol, MA; Dinc, V; Esatoglu, SN; Kamat, S; Kostek, ME; Sargin Altunok, E; Satici, C; Toprak, ID; Yazla, S | 1 |
2 review(s) available for methylprednisolone and favipiravir
| Article | Year |
|---|---|
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Glucocorticoids; Guanidines; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Recovery of Function; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
5 other study(ies) available for methylprednisolone and favipiravir
| Article | Year |
|---|---|
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Methylprednisolone; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid.
Topics: Adrenal Cortex Hormones; Aged; Amides; Antiviral Agents; COVID-19; Extracorporeal Membrane Oxygenation; Humans; Male; Methylprednisolone; Middle Aged; Pyrazines; Respiration, Artificial; Respiratory Insufficiency; SARS-CoV-2 | 2021 |
Myositis due to COVID-19.
Topics: Adult; Amides; Antiviral Agents; C-Reactive Protein; COVID-19; COVID-19 Nucleic Acid Testing; Creatine Kinase; Fibrin Fibrinogen Degradation Products; Glucocorticoids; Humans; Hydroxychloroquine; Lung; Lymphopenia; Magnetic Resonance Imaging; Male; Methylprednisolone; Muscle, Skeletal; Myositis; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed | 2021 |
A case report of super responder of critical COVID-19 pneumonia.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Glucocorticoids; Humans; Lung; Male; Methylprednisolone; Pneumonia, Viral; Pyrazines; Receptors, Interleukin-6; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Care; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Male; Methylprednisolone; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Turkey | 2022 |